TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00998010
Drug: bortezomib + temozolomide+ radiation therapy
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200 centigray (cGy) daily doses to a total dose of 6000 cGy.
Study: NCT02185300
Drug: Dolutegravir Pediatric Granules
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
Study: NCT02185300
Drug: Dolutegravir Dispersible Tablet
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
Study: NCT01444300
Drug: Dalfampridine
Normalized name: Dalfampridine
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg, bid, pill taken by mouth for 12 weeks
Study: NCT01818687
Drug: colestilan
Normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
Study: NCT01885988
Drug: Nebivolol
Normalized name: Nebivolol
DrugBank: Nebivolol (DB04861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
Study: NCT01885988
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
Study: NCT01656577
Drug: Pexacerfont
Normalized name: Pexacerfont
DrugBank: Pexacerfont (DB12572)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04089514
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as specified in the treatment arm
Study: NCT02252965
Drug: Metformin IR
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
Study: NCT02252965
Drug: Metformin XR
Normalized name: metformin Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
Study: NCT03300921
Drug: Paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Product: Paricalcitol~Dose/Route/Regimen:~Arm A: 50mcg IV weekly Arm B: 12mcg PO daily
Study: NCT00337792
Drug: oxycodone + lorazepam versus fentanyl + midazolam
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01521299
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral hydroxyurea on days 1,8 and 15
Study: NCT01981681
Drug: PF-06263726
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
Study: NCT01981681
Drug: PF-06263726
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
Study: NCT01981681
Drug: PF-06263726
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study: NCT06043336
Drug: Dexamethasone, granisetron & palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: . Group A received 1 ml of intravenous (IV) 0.9% saline after intubation and IV palonosetron 0.075 mg at the end of operation. Group B received IV dexamethasone 4 mg after intubation and IV granisetron 1 mg at the end of surgery
Study: NCT01100112
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
Study: NCT02831660
Drug: idarucizumab
Normalized name: Idarucizumab
DrugBank: Idarucizumab (DB09264)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00678730
Drug: delta 9 tetrahydrocannabinol
DrugBank: Cannabinol (DB14737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Study: NCT02160288
Drug: Botulinum Toxin-A
Normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: 100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
Study: NCT00938301
Drug: PF-04455242
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
Study: NCT00490542
Drug: ziprasidone (Geodon)
Normalized name: ziprasidone Injection [Geodon]
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
Study: NCT03249194
Drug: Direct acting Anti-Viral Therapy using Epclusa or Zepatier
Normalized name: Zepatier
DrugBank: Elbasvir (DB11574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
Study: NCT02070653
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00020748
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00020748
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00293176
Drug: Donepezil Hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
Study: NCT00006379
Drug: fludarabine phosphate
Normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: fludarabine IV over 30 minutes on days -8 to -4
Study: NCT01589614
Drug: PH-797804
Normalized name: PH-797804
DrugBank: PH-797804 (DB07941)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, 6mg, single
Study: NCT00413114
Drug: Obatoclax mesylate (GX15-070MS)
Normalized name: mesylate
DrugBank: Obatoclax (DB12191)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00668759
Drug: Vernakalant Injection
DrugBank: Vernakalant (DB06217)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
Study: NCT00668759
Drug: Amiodarone Injection:
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
Study: NCT01981681
Drug: PF-06263726
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
Study: NCT00914576
Drug: Vitamin and mineral supplement
Normalized name: Vitamin and Mineral Supplement
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
Study: NCT00914576
Drug: Vitamin and mineral supplement
Normalized name: Vitamin and Mineral Supplement
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
Study: NCT00914576
Drug: 100% Oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: breathing of 100% O2 for 30 minutes on both study days
Study: NCT00914576
Drug: Escherichia coli Endotoxin
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
Study: NCT00244192
Drug: infliximab (Remicade)
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03816176
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous (IV) infusion
Study: NCT03816176
Drug: Isavuconazonium sulfate
Normalized name: Isavuconazonium Sulfate
DrugBank: Isavuconazonium (DB06636)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral capsule
Study: NCT00712478
Drug: insulin
Normalized name: Insulin
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study: NCT01131897
Drug: Levetiracetam
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Study: NCT03583229
Drug: Aspirin 75mg
Normalized name: ASPIRIN 75MG CHEW TAB
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days treatment with 75 mg aspirin daily.
Study: NCT03326245
Drug: Methylphenidate Pill
Normalized name: methylphenidate Pill
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylphenidate (60 mg) given 30 minutes prior to bolus \[11C\]raclopride
Study: NCT03326245
Drug: Intravenous methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylphenidate 0.25 mg/kg in 3ml sterile saline given 30 minutes post bolus injection of \[11C\]raclopride.
Study: NCT02180828
Drug: Clotrimazole vaginal tablet
Normalized name: clotrimazole Vaginal Cream
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
Study: NCT02180828
Drug: Fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 doses of 150 mg oral Fluconazole (at day1 and day4)
Study: NCT03376516
Drug: Wilate
Normalized name: Wilate
DrugBank: Von Willebrand factor human (DB13133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: von Willebrand factor / Factor VIII (plasma derived)
Study: NCT01941602
Drug: prophylactic enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
Study: NCT01370876
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
Study: NCT01047189
Drug: clindamycin phosphate 1.2% and tretinoin 0.025%
Normalized name: clindamycin phosphate 12 mg in 1 g / tretinoin 0.25 mg in 1 g TOPICAL GEL [Clindamycin Phosphate 1.2% and Tretinoin 0.025%]
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: applied once daily for 12 weeks
Study: NCT00706147
Drug: Arimoclomol
Normalized name: arimoclomol
DrugBank: Arimoclomol (DB05025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: Arimoclomol capsules given three times per day
Study: NCT01370187
Drug: Montelukast
Normalized name: Montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast 4mg daily for 2 months
Study: NCT00284180
Drug: Vinflunine
Normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel second generation vinca alkaloid
Study: NCT00284180
Drug: Trastuzumab
Normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-HER2 monoclonal antibody
Study: NCT01544673
Drug: linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 600 mg oral tablet twice daily for 4.5 days
Study: NCT01905540
Drug: SSP-004184AQ
Normalized name: Cercidium floridum ssp. floridum pollen
DrugBank: Parkinsonia florida pollen (DB11006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium salt
Study: NCT01905540
Drug: SSP-004184SS
Normalized name: Cercidium floridum ssp. floridum pollen
DrugBank: Parkinsonia florida pollen (DB11006)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disodium salt
Study: NCT01727934
Drug: Miravirsen sodium
Normalized name: Miravirsen
DrugBank: Miravirsen (DB12851)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection
Study: NCT00216281
Drug: Clozapine augmented with atomoxetine up to 40 mg or placebo
Normalized name: atomoxetine 40 MG
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01451411
Drug: Conivaptan hydrochloride
Normalized name: Conivaptan Hydrochloride
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous
Study: NCT00020254
Drug: nilutamide
Normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04034134
Drug: Jaktinib Hydrochloride Tablets
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg twice-daily (BID)
Study: NCT04034134
Drug: Jaktinib Hydrochloride Tablets
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg quaque die (QD)
Study: NCT04034134
Drug: Jaktinib Hydrochloride Tablets
Normalized name: sevelamer hydrochloride Oral Tablet
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg quaque die (QD)
Study: NCT00133627
Drug: Ketotifen
Normalized name: Ketotifen
DrugBank: Ketotifen (DB00920)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03147183
Drug: Thymoglobulin
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
Study: NCT00535418
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099396
Drug: Docetaxel+lobaplatin
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02099396
Drug: Gemcitabine+lobaplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00198471
Drug: Vitrase
Normalized name: Vitrase
DrugBank: Hyaluronidase (ovine) (DB00070)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02507154
Drug: Cetuximab + NK cells
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00577200
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam
Study: NCT00577200
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
Study: NCT04513808
Drug: Propofol-based total intravenous anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol-based total intravenous anesthesia, titrated to clinical need.
Study: NCT04513808
Drug: Sevoflurane intravenous anesthesia
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sevoflurane intravenous anesthesia, titrated to clinical need.
Study: NCT02865174
Drug: Topical tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
Study: NCT02865174
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
Study: NCT00973739
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response.
Study: NCT00982488
Drug: Dasatinib
Normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dasatinib was supplied as 20- and 50-mg tablets.
Study: NCT00982488
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib was supplied as 100- and 400-mg tablets.
Study: NCT01662908
Drug: edoxaban tosylate
Normalized name: Edoxaban Tosylate
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
Study: NCT01662908
Drug: warfarin
Normalized name: Warfarin
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
Study: NCT01759030
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
Study: NCT00531232
Drug: Clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pharmaceutical form: Tablet,~Route of administration: Oral
Study: NCT04941196
Drug: Anplag (Ticagrelor 90 mg)
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg Immediate Release tablet
Study: NCT04941196
Drug: Brilinta (Ticagrelor 90 mg)
Normalized name: Brilinta
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg Immediate Release tablet
Study: NCT03892161
Drug: Darunavir/ritonavir 800/100 mg tablet
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Standard dose DRV/r administered
Study: NCT03796910
Drug: SPR720 for SAD
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 8 dose ascending cohorts) to receive either SPR720 or placebo. The study drug (SPR720 or placebo) will be administered as a single dose.
Study: NCT02762266
Drug: lipiodol
Normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03978845
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using an ultrasound and a nerve stimulator, the phrenic nerve will be identified and low-dose lidocaine will be administered perineurally.
Study: NCT03398330
Drug: Oxycodone Tamper Resistant
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Orally taking Oxycodone Tamper Resistant 40mg in fed state
Study: NCT01143402
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV